Analyst Ratings for Kymera Therapeutics (KYMR)
KYMR Rating Summary
KYMR Price Target Summary
- Highest: $170.00 (Guggenheim)
- Lowest: $97.00 (Brookline Capital Markets)
- Average: $133.79
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$133.79 (+27.7%)
* Over Last 12-Mos
Rating Score: 8.7 / 10
Percentile Rank: 87%
Rating Score: 8.7 / 10
Percentile Rank: 87%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/8/2026 | Raymond James | Thomas Deal | New Coverage | Outperform (N/A) |
140.00 (N/A) |
108.35 (104.78) |
-3.29% | Details |
| 9/24/2026 | Goldman Sachs | Andrea Newkirk | New Coverage | Early-Stage Biotech (N/A) |
N/A (N/A) |
115.47 (104.78) |
-9.26% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
